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As costly stem cell treatments progress from experimental concepts toward licensed products and routine
procedures, governmental and private payers grapple with shrinking budgets to cover more lives. We
describe efforts underway in the US to create mechanisms for reimbursement of cell therapies and discuss
other reimbursement-related issues for the stem cell community.Cell therapy, previously the exclusive
domain of hematopoietic stem cell trans-
plantation (HSCT), is rapidly extending
into newer cardiovascular, neurodegen-
erative, cerebrovascular, and endocrine
applications, as well as tissue and organ
replacement. However, despite the fast
pace of the science and medicine, the
availability of reimbursement for these
applications is progressing slowly, for
a number of reasons; most importantly,
to date there are few marketed cell thera-
pies in the US, much less marketed stem
cell therapy products. Therefore, payers,
both governmental and private, have not
had to make major coverage decisions
in the stem-cells-as-products arena. In
order to ensure that future commercial
and clinical applications of stem cell prod-
ucts will be reimbursable, researchers
should consider lessons learned by the
HSCT field. While a US-centric perspec-
tive is highlighted here, analogous insight
can be extrapolated to international
efforts in this regard. Without establishing
a development strategy that allows for the
reimbursement of providers for an applied
clinical product, even the most effective
therapy may not make it off the shelves.
Lessons from the Past: HSCT
as a Model
Today’s emerging cellular therapy field
is firmly rooted in the development of
HSCT, which stems frommultiple preclin-
ical investigations, early attempts at
adoptive therapeutic marrow transfer to
terminal patients, and the first success-
ful allogeneic transplantation procedure
performed in 1968. Multiple refinements
and expanded attempts to use cellulartherapy followed, and by 1980, marrow
allografting was no longer viewed as
‘‘experimental,’’ but rather was recog-
nized as acceptable therapy for patients
with a variety of hematologic disorders.
As such, reimbursement became avail-
able from governmental and private
payers and was soon thereafter ex-
tended to autologous transplantation.
New patient-specific initiatives, including
ex vivo purging of bone marrow of T cells
as a means to reduce the risk of GVHD
and for purging minimal residual disease,
expanded the potential applications of
HSCT. During this decade, coverage
was in the form of indemnity insurance,
also known as ‘‘fee-for-service’’ and,
consequently, there was significant finan-
cial incentive for clinical performance
and expansion of transplant procedures.
Perhaps in response to the predicted
financial impact of transplantation, in
1987 the state of Oregon opted to no
longer provideMedicaid support for trans-
plant procedures (bone marrow, liver,
kidney, heart) to avoid favoring the expen-
sive needs of a few over the resulting
financial restrictions placed on the many
(Welch and Larson, 1988). Seven years
later, the creation of the Oregon Health
Plan reversed this decision, and reim-
bursement decisions for specific cases
were based on rankings of evidence-
based efficacy of therapies, not costs
(Bodenheimer, 1997a, 1997b).
During the 1990s, cell therapy was
primarily used to treat hematologic malig-
nancies. However, while individual blood
cancers remain classified as orphan
diseases (defined as less than 200,000
individuals in the US), the potentialCell Stem Capplication of HSCT to solid tumor malig-
nancies such as breast, ovarian, and
lung cancer dramatically expanded the
numbers of transplant candidates, magni-
fying the potential financial impact on
healthcare budgets. Consequently, previ-
ously collaborative relationships between
payers and cell therapists were strained,
and therapeutic decisions were some-
times made in court rooms rather than in
well-designed clinical trials. As a conse-
quence, the national Blue Cross’ Demon-
stration Project was initiated to provide
support for autologous transplantation in
indications such as multiple myeloma
and high risk or metastatic breast cancer,
but only (1) in the setting of well-designed,
phase 3 clinical trials, and (2) within
boundaries of a predetermined target
financial case rate. Evidence-based
medicine in conjunction with managed
care was the focus, and many payers
followed suit, effectively contributing to
the development of transplant access
networks.
Another landmark in the evolution of
reimbursement for cell therapy was the
FDA’s decision to equate the administra-
tion of cells with the utilization of a
‘‘drug’’ (Fink, 2009; Halme and Kessler,
2006). As of May 2005, the FDA must
rule whether any human application of
cells or tissues requires regulation for
a given context. In effect, cells and cell
therapymoved out of the realm of medical
practice and into the pharmacological
drug sphere. In the HSCT arena, most
standard current practices still remain
exempt, but any nonminimal manipulation
will require FDA oversight, including the
current utilization of cord blood unitsell 8, June 3, 2011 ª2011 Elsevier Inc. 609
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the classification of cells as drugs pro-
vides some clarity as to the applicable
regulations, it also inherently drives up
the cost of the final product and, there-
fore, the overall costs to the health
care system. Further, it adds a new level
of complexity to the questions of how
clinicians claim reimbursement for vary-
ing forms of cell therapy and how
much reimbursement payers will provide.
Any researcher, clinician, or commercial
enterprise desiring to provide a patient
population with cell therapy must learn
to navigate their local reimbursement
system, and it is wise to be aware of these
workings before a potential therapy is
ready for entry into any market.
Reimbursement and
Reimbursement Codes
The pathway to reimbursement for both
products and services can be extremely
complex, as it varies with national and
local government, as well as with
private payers. (For detailed descriptions
of reimbursement pathways in multi-
ple countries, see http://www.ispor.org/
HTAspecialissue/index.asp/.)
Payments to providers for those reim-
bursed products and services are even
more complex and are based upon
whether a patient is funded by a govern-
mental plan (generally, The Centers for
Medicare & Medicaid Services [CMS] in
the US) or has payer support from a range
of private insurer options. However, most
plans follow the governmental CMS payer
approach, which is based on the diag-
nosis-related group (DRG) reimburse-
ment strategy for inpatient services.
DRGs bundle the labor and nonlabor
resources that are used to treat patients
in a hospital with a particular disease or
disorder. These payments are designed
to cover routine costs attributable to
patient care, and payment is based on
the average costs of a particular diag-
nosis. Standard rates can be increased if
the patient has complicating conditions,
but not if more expensive agents are
substituted for less expensive ones in
the absence of complicating conditions.
Similarly, ambulatory payment classifica-
tions (APCs) are used for determination
of reimbursement for outpatient services.
Thus, both DRGs and APCs have upper
limits of reimbursement, and if the
provider exceeds those limits due to the610 Cell Stem Cell 8, June 3, 2011 ª2011 Elsuse of a more expensive therapy such as
a pricey stem cell treatment, then the
excess expense is not reimbursed. There-
fore, developers of stem cell products
should be aware of the DRGs and
APCs applicable to their cell therapy that
define the upper limit of reimbursement
a provider can currently expect.
Establishing reimbursement to a pro-
vider has two major components: the
unique alphanumeric code designated
for the candidate product or service and
the financial amount assigned to that
code. Since review of clinical intervention
is retrospective, payers must have clear
and highly specific definitions of the
products, procedures, and services per-
formed for a patient in order to provide
the assigned amount of financial compen-
sation to the provider. These descriptions
are captured in the codes.
Of import in the context of the stem cell
field: if a code doesn’t exist, then for all
intents and purposes there is no routine
method for a health care provider or
a company selling the stem cell product
to be paid by an insurer for that product
or service. For example, the original
bone marrow transplant cell processing
code was a single blood bank code that
was subsequently divided into several
independent codes, covering various pro-
cessing technologies including T cell,
platelet or RBC depletion, or tumor cell
purging (Gajewski et al., 2005). Unfortu-
nately, the refinement of the coding
lagged behind the evolution of the tech-
nology, and it took years for CMS and
payers to accept the subdivided codes
as standard. As a consequence, some
investigators feel that the adaptation
and further exploration of T cell depletion
was delayed due to fear of lack of
reimbursement, despite FDA approval of
devices that could provide a T cell
depleted allogeneic product.
Despite these caveats, progress has
been made to define more specific codes
that will be the basis of reimbursement
for the developing fields of cell therapy
and regenerative medicine. Table 1 lists
some of the relevant codes and their
corresponding current reimbursement
rates. The rates are continually adjusted
and can either increase or decrease over
time. Notably, within the current CPT
codes, the actual administration of cells
is limited to intravenous infusion of alloge-
neic or autologous hematopoietic stemevier Inc.cell products or to the intravenous admin-
istration of unmanipulated allogeneic
donor lymphocytes with the purpose of
providing the graft versus malignancy
effect.
Considering the vast number of poten-
tial indications, not to mention alternative
sources of emerging cell therapies, it is
clear that additional codes will be
required. Many new therapies will require
novel procurement protocols, GMP pro-
cessing, storing of cell products, and,
possibly, novel delivery systems. Using a
still-experimental protocol as an example,
if autologous bone marrow mononuclear
cells are harvested and then directly
injected intramuscularly into a lower
extremity to treat critical limb ischemia,
one can string together a list of codes
that might be provided to gain reimburse-
ment. However, based on the track record
observed in HSCT, any rapid adjustment
to existing codes seems unlikely. Thus, if
current and future trials confirm a thera-
peutic benefit in critical limb ischemia,
advocates must also pursue adoption of
the appropriate reimbursement codes,
bundling the procedure codes with diag-
nosis. For a commercial effort, planning
ahead for such an eventuality could
make the difference between success
and failure, irrespective of the effective-
ness of the treatment itself.
Reimbursement Rate
Despite today’s widespread reimburse-
ment coverage of stem cell transplants
in the hematology/oncology setting, it is
frequently inadequate and difficult to navi-
gate for complicated cases due to the
case rate structure of reimbursement
that has evolved. New stem cell therapy
products will likewise be faced with
several difficult years, during which time
the sponsors will need not only to obtain
appropriate codes, but negotiate the
reimbursement rate for that code, poten-
tially in the setting of the elderly patient
with other comorbid conditions.
For both autologous and allogeneic cell
therapies, new pricing and reimburse-
mentmodelsmay includeDRG-like codes
that encompass the multiple clinic, lab,
and GMP manufacturing activities, as
well as the products and services neces-
sary to deliver them. Thus, when setting
a price for their cell product, sponsors
will need to consider not only their costs
of goods sold (COGS) plus their desired
Table 1. Reimbursement Codes and Rates for Selected Transfusion, Apheresis, and






36511 Apheresis wbc $853.18 5.99%
36515 Apheresis, adsorp/reinfuse $2,166.33 -3.55%
36516 Apheresis, selective $2,166.33 -3.55%
36522 Photopheresis $2,166.33 -3.55%
38206 Harvest auto stem cells $853.18 5.99%
38207 Cryopreserve stem cells $233.61 2.51%
38208 Thaw preserved stem cells $233.61 2.51%
38209 Wash harvest stem cells $233.61 2.51%
38210 T-cell depletion of harvest $418.39 7.25%
38211 Tumor cell deplete of harvest $418.39 7.25%
38212 Rbc depletion of harvest $418.39 7.25%
38213 Platelet deplete of harvest $418.39 7.25%
38214 Volume deplete of harvest $418.39 7.25%
38215 Harvest stem cell concentrate $418.39 7.25%
38220 Bone marrow aspiration $257.53 23.25%
38221 Bone marrow biopsy $257.53 23.25%
38230 Bone marrow collection $2,166.33 -3.55%
38240 Bone marrow/stem transplant (allogeneic) $2,166.33 -3.55%
38241 Bone marrow/stem transplant (autologous) $2,166.33 -3.55%
38242 Lymphocyte infuse transplant $853.18 5.99%
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impact of all ancillary products and
services needed to deliver the cell
product. Sponsors are encouraged to
collect costs data throughout their
product development in order to substan-
tiate their desired price and to support
appropriate reimbursement for the DRG.
Costs include all expenditures for the
development phases of the product, as
well as for the commercial production.
Of course, costs data alone are not suffi-
cient to justify a price and future reim-
bursement rates, and permanent codes
will be based upon a payer’s review of
the data supporting a product or service’s
clinical effectiveness, its comparative
effectiveness, and long-term economic
outcomes.
That said, it is important to note that
issuance of permanent codes and a reim-
bursement rate do not guarantee usage.
Some reimbursed drugs are not widely
utilized, often because the single drug’s
cost alone could consume significant
amounts of the DRG payment. For exam-
ple, plerixafor is a small molecule inhibitor
of the SDF1 receptor CXCR3 and has
been FDA approved for hematopoietic
stem cell mobilization in conjunction withG-CSF. The $6000+ cost/vial of the agent
may be offset by avoiding additional
apheresis and stem cell cryopreservation,
but most institutions have developed
restrictive algorithms for its utilization
based on pre-existing fixed case rates in
order to protect against financial losses
(Shaughnessy et al., 2011).
Product costs can also affect medical
practice due to the lag between rapid
changes in clinical methods versus slower
changes in reimbursement rates; for
example, adult recipients of umbilical
cord blood transplantation are increas-
ingly receiving dual cord transplants
based on improved clinical outcomes in
advanced clinical trials. However, centers
that pursue this therapy often receive
a fixed bundled payment based on the
acquisition cost of a single cord blood
product. Consequently, the hospital or
other provider generally absorbs the
$30,000–$50,000 additional cost of the
second cord. This expense is accepted
with the expectation that long-term
complications (and corresponding costs)
may beminimized for dual cord transplant
patients.
Thus, in a world with cells-as-drugs
and evolving health care reform, healthCell Stem Csystems will be motivated to consider
fiscal austerity, payer systems will mea-
sure both quality measures and cost of
care, and commercial entities will need
to be careful not to price themselves out
of the market, all activities which could
contribute to slowing the expansion of
regenerative medicine (Nugent, 2011).
Finally, and unfortunately, much attention
in health care remains on tangible, short-
term cost containment, as opposed to
assessing the longer term economic and
human impact of failing to pursue thera-
pies for an aging population.
Reimbursement for Cell Therapies
In the US, there are a handful of FDA-
approved cell therapies that are generally
covered by payers. These include prod-
ucts such as Dermagraft and Carticel
and the latest entrant, Provenge (Cham-
bers and Neumann, 2011; Goozner,
2011). The latter is an autologous
dendritic cell therapy for use in advanced
prostate cancer and costs approximately
$93,000 for a three dose course of
therapy. In response to the price tag and
potentially large number of patients,
CMS conducted its own review of the
safety and efficacy of the product before
announcing, almost a year later, that it
would provide national coverage, strictly
in line with the approved FDA indication.
Provenge is currently using a temporary
code often assigned to new drugs, and
codes applied for the clinical and lab
services necessary for its use are taken
from existing procedures. While this
approach is adequate for Provenge, the
same may not be true for more complex
stem cell products.
An older example of a reimbursed cell
therapy is Carticel (autologous cultured
chondrocytes). Carticel is generally used
in a young patient population and is
covered at different rates depending on
the patient’s health insurance policy.
CMS is not tremendously affected by
Carticel due to the age of the patients
and the relatively infrequent use of the
product; however, a number of new cell-
based cartilage repair products are in
development and many are likely to be
used in seniors, CMS’s largest covered
population. Thus, reimbursement for
these products is likely to attract substan-
tial review. While Carticel does have a
unique and permanent code, its applica-
tion to newer cartilage cell therapies isell 8, June 3, 2011 ª2011 Elsevier Inc. 611
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the description of the new cartilage-
replacement products and cell process-
ing services aswell as in the dollar amount
covered.
For emerging cell therapies, depending
on how the cells are sourced, processed,
stored, and administered, as well as on
the product’s indication, reimbursement
codes may not yet exist. Developers of
such therapies need to determine very
early what the existing relevant codes
and rates may be. Existing codes may
apply in terms of the procedural descrip-
tion, but may fall far short of covering the
product’s costs, much less its price.
Current Advocacy Efforts
As outlined above, the first hurdle to
achieving reimbursement for stem cell
products is to create codes where there
are none. Ultimately, community advo-
cacy is required, along with a significant
commitment of time and personnel to
support the evolution of the coding
system. Many professional organizations
contribute to theseefforts, but theprocess
can be costly and often hinges on a few
interested and committed individuals.
In the case of cell therapy, organizations
such as the National Marrow Donor
Program (NMDP), the American Associa-
tionofBloodBanks, andAmericanSociety
for BoneMarrow Transplant do contribute
to these efforts; however, future advocacy
will likely stem from tissue-specific socie-
ties such as the American Vascular Asso-
ciation’s efforts in support of cell therapy
for critical limb ischemia as well by
focused stem cell societies. For example,
the Alliance for Regenerative Medicine
combines commercial, academic, and
not-for-profit institutional members in its
mission to educate policymakers and to
advocate for favorable public policies for612 Cell Stem Cell 8, June 3, 2011 ª2011 Elsfunding, reimbursement, and regulatory
issues. Additionally, ongoing education
of hospital billing systems is critical to
ensure the accurate collection of data
and submission of appropriate documen-
tation toCMSandother payers. In a recent
NMDP evaluation of transplant centers,
widespread failure to report accurate indi-
vidual donor or cellular acquisition costs
was observed (M. Boo, personal commu-
nication). This incomplete cost reporting
ultimately contributes to the underfunding
of procedures.
Looking Ahead
In many countries, exciting stem cell ther-
apies are in early stages of clinical devel-
opment; however, if the billing codes are
not legally in place to describe the proce-
dures and products, and if adequate
coverage is not provided by payers,
patients will gain nothing from these
medical advances.
Sponsors wishing to bring new stem
cell therapies to market cannot only focus
on regulators’ requirements for approval,
but must also consider payers’ require-
ments. Recently, CMS and FDA sought
public commentary on a proposal to
conduct parallel review of new device
and new drug applications. At this point,
a pilot program for parallel review of
devices appears likely and, pending
the results, the FDA and CMS will
consider expanding the program to
include new drug applications. Simulta-
neous evaluation of endpoints for thera-
pies by these two US agencies might
streamline the path to market. Indeed,
a parallel review approach is already in
place in many countries with nationalized
health services.
As seen during the long history of HSCT
and the recent experience with Provenge,
reimbursement for expensive, intricate,evier Inc.personalized medicines is possible. Suffi-
cient reimbursement, however, is not
guaranteed, nor even necessarily tied to
clinical effectiveness. In order to help
themselves help patients, all sponsors
who ultimately hope to register their
product in the US will do well to partici-
pate in the requests from CMS and FDA
to provide feedback on the proposed
parallel review process and to participate
in the ongoing advocacy efforts to create
proper billing codes with adequate reim-
bursement values. The involvement of
international societies that advocate for
responsible translation of stem cell-medi-
ated therapies might also allow different
regulatory bodies to learn from one
another.
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